| | 720690-73-3 Basic information More.. |
| Product Name: | GSK 189254A | | Synonyms: | GSK 189254A;6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-MethylnicotinaMide;N-(4-METHOXYBENZYL)-1-[(4-METHYLPHENYL)SULFONYL]-1H-PYRROLO[2,3-B]PYRIDIN-4-AMINE;6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methylpyridine-3-carboxamide;histamine H3 receptor antagonist GS189254A;CS-2905;3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-;Histamine Receptor,GSK-189254,GSK 189254,GSK-189254A,inhibit,GSK189254A,Inhibitor | | CAS: | 720690-73-3 | | MF: | C21H25N3O2 | | MW: | 351.44 | | EINECS: | | | Mol File: | 720690-73-3.mol |  |
Use
GSK189254A is a histamine H3 receptor antagonist for the treatment of narcolepsy.It may also be useful for the treatment of dementia and neuropathic pain. Its pharmacological effect may be related to its effect on increasing the release neurotransmitter in the brain. Microdialysis studies demonstrated that GSK189254 increased the release of acetylcholine, noradrenaline, and dopamine in the anterior cingulate cortex and acetylcholine in the dorsal hippocampus. GSK189254 significantly improved performance of rats in diverse cognition paradigms, including passive avoidance, water maze, object recognition, and attentional set shift. These data suggest that GSK189254 may have therapeutic potential for the symptomatic treatment of dementia in Alzheimers disease and other cognitive disorders.
|
|
720690-73-3
Recommend Suppliers |
|